Meeting
2014 ASCO Annual Meeting
Phase II trial of panitumumab plus FOLFOX4 or FOLFIRI in subjects with KRAS wild-type colorectal cancer and liver-limited disease: The PLANET study.
Authors
Albert Abad
University Hospital Germans Trias i Pujol-ICO, Barcelona, Spain
Albert Abad , Bartomeu Massuti , Cristina Gravalos , Pilar Escudero , Carmen Guillen , Jose Luis Manzano , M.Auxiliadora Gomez , Maria Jose Safont , Javier Gallego Plazas , Javier Sastre , Carles Pericay , Rosario Dueñas , Carlos López-López , Ferran Losa , Manuel Valladares Ayerbes , Encarnación González , Ana Yuste , Alfredo Carrato , Enrique Aranda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00885885
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3560)
DOI
10.1200/jco.2014.32.15_suppl.3560
Abstract #
3560
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A randomized multicenter phase II study of FOLFIRI plus either panitumumab (Pmab) or bevacizumab (Bmab) as second-line treatment for wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) with exploratory biomarker analysis by liquid biopsy: WJOG6210G.
First Author: Kohei Shitara
Poster
2012 Gastrointestinal Cancers Symposium
Efficacity and safety of panitumumab in mCRC patients: A post-AMM OMIT study.
First Author: Francoise Grude
Poster
2011 Gastrointestinal Cancers Symposium
Outcome according to metastatic site in patients with KRAS wild-type tumors: Analysis from the CRYSTAL and OPUS studies.
First Author: Eric Van Cutsem
Poster
2023 ASCO Annual Meeting
RAS testing of circulating cell-free DNA (cfDNA) from tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients: Preliminary data from the Liquid Biopsy Monoclonal Antibodies in mCRC (LIBImAb) study.
First Author: Anna Maria Rachiglio